Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.79 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.79 |
| ▸ | LMNA | P02545 | 3/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | PPARG | P37231 | 1/20 | 0.58 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4515693 | 0.91 | KMT2A (0.80) | KMT2ARXFP1NPSR1LMNAKCNH2 | |
| SCHEMBL4505873 | 0.90 | KMT2A (0.64) | KMT2ARXFP1NPSR1LMNAKCNH2 | |
| SCHEMBL3492155 | 0.88 | KMT2A (0.60) | KMT2ARXFP1NPSR1LMNAKCNH2 | |
| SCHEMBL4520845 | 0.87 | KMT2A (0.78) | KMT2ARXFP1NPSR1LMNAKCNH2 | |
| SCHEMBL4527847 | 0.82 | KMT2A (0.80) | KMT2ARXFP1NPSR1LMNAKCNH2 | |
| SCHEMBL4524904 | 0.82 | KDM4E (0.55) | KMT2ARXFP1NPSR1LMNAKCNH2 | |
| SCHEMBL4517936 | 0.81 | KMT2A (0.69) | KMT2ARXFP1NPSR1LMNAKCNH2 | |
| SCHEMBL4514505 | 0.81 | KMT2A (0.65) | KMT2ARXFP1NPSR1LMNAKCNH2 | |
| SCHEMBL4507545 | 0.81 | KMT2A (0.67) | KMT2ARXFP1NPSR1LMNAKCNH2 | |
| SCHEMBL4520410 | 0.80 | KMT2A (0.66) | KMT2ARXFP1NPSR1LMNAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1908765-B1 | THIENOPYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2014-10-22 | — | — | EP | disclosed |
| US-8377944-B2 | Thienopyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20130023546-A1 | THIENOPYRIMIDINE DERIVATIVES | GOTANDA KOTARO (JP) | 2013-01-24 | — | — | US | disclosed |
| US-8293754-B2 | Thienopyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20090203703-A1 | Thienopyrimidine Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-1908765-A1 | THIENOPYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023546-A1 | THIENOPYRIMIDINE DERIVATIVES | PDE9A, BPHL, THOP1 | KMT2A 2650/4885RXFP1 739/4885NPSR1 476/4885 |
| US-20090203703-A1 | Thienopyrimidine Derivatives | PDE9A, BPHL, THOP1 | KMT2A 2650/4885RXFP1 739/4885NPSR1 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.